Bill
Bill > HR2038
US HR2038
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
summary
Introduced
04/02/2019
04/02/2019
In Committee
05/15/2019
05/15/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes. 1
AI Summary
This bill, the State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019, aims to allow private health insurance issuers to jointly negotiate wholesale acquisition prices of prescription drugs with manufacturers. The bill provides an antitrust exemption for such negotiations, as long as no single wholesale acquisition price is jointly determined between the insurance issuers or their agents. The key terms defined in the bill include "antitrust laws," "health insurance issuer," "health maintenance organization," and "manufacturer." The bill would take effect upon enactment and would not apply to conduct that occurred before the date of enactment.
Committee Categories
Government Affairs, Justice
Sponsors (3)
Last Action
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (on 05/15/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/2038/all-info |
| BillText | https://www.congress.gov/116/bills/hr2038/BILLS-116hr2038ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr2038/BILLS-116hr2038ih.pdf.pdf |
Loading...